The low in vivo transduction efficiency of recombinant adeno-associated virus (rAAV) and the undesirably strong immunogenicity of adenovirus (rAdv) have limited their clinical utilization in cancer gene therapy. We have previously demonstrated that intratumoral injection of rAAV expressing a C-terminal polypeptide of human telomerase reverse transcriptase (rAAV-hTERTC27) effectively inhibits the growth of glioblastoma xenografts in nude mice. To further improve its efficacy, we combined rAAVhTERTC27 with rAdv and investigated the efficiency of the cocktail vectors in vivo. At a nontherapeutic dose (1 Â 10 8 plaqueforming units (PFUs)), rAdv-null and rAdv-hTERTC27 were equipotent in enhancing the therapeutic efficacy of rAAV-hTERTC27 (1.5 Â 10 11 v.g.), and complete tumor regression was achieved in 25% of the treated animals. Importantly, the combination of rAAVhTERTC27 and a therapeutic dose (2.5 Â 10 9 PFU) of rAdv-hTERTC27 significantly augmented the therapeutic effects and led to a 38% complete tumor regression rate. In vivo optical imaging also showed that rAAV-luc/rAdv-luc cocktail vectors could synergistically enhance the early transient and latent sustained expression of luciferase, as compared to rAdv-luc and rAAV-luc alone. These findings suggest that the combination of rAAV-hTERTC27 and a therapeutic dose of rAdv-hTERTC27 is potentially a promising treatment for glioblastoma, and the rAAV/rAdv cocktail vector system warrants further development for cancer gene therapy.
Introduction
Glioblastoma multiforme (GBM, World Health Organization grade IV), which originates from poorly differentiated astrocytes, is the most common and most severe type of brain tumor. Despite multimodal treatments such as resection, chemotherapy and radiotherapy, the prognosis of GBM remains poor and the median survival is only 12-15 months. 1 There are several reasons to explain why current therapies have limited benefit to the GBM patients. First, GBM cells diffusely infiltrate the surrounding brain structures, making complete resection impossible. Second, GBM has high resistance to radiation. Third, the existence of the blood-brain barrier in the brain limits the penetration of chemotherapeutic agents into the tumor. Therefore, the development of new therapeutic strategies for GBM is urgently required.
Contrary to other cancers, GBM is an attractive target for local gene therapy because of its restricted anatomical location and the absence of extracranial metastases. This allows the delivery of vectors directly to the desired site with a relatively low risk of systemic toxicity. Several gene therapy strategies have been applied for the treatment of GBM, 2 and one of the most popular methods is to deliver therapeutic genes for GBM by recombinant adenoassociated virus (rAAV). rAAV vector promises safe, efficient and long-term in vivo gene transfer in numerous tissues. 3 Different from the wild-type AAV, rAAV vectors do not preferentially integrate at the AAVS1 loci. Rather, they can either persist as episomes (especially in nondividing cell populations) 4 or randomly integrate into the genome. [5] [6] [7] Clinical trials using rAAV to target GBM cells have already demonstrated their safety and efficiency. 8, 9 However, the preparation of large quantities of rAAV vectors for clinical studies is labor-intensive and costly. 10 We have previously reported that expression of a truncated 27-kDa C-terminal fragment of hTERT (hTERTC27) inhibits growth and tumorigenicity of human cervical cancer HeLa cells. 11 It also renders HeLa cells sensitive to H 2 O 2 -induced oxidative stress and induces cell senescence, without inhibiting endogenous telomerase activity. 12 Furthermore, we have recently demonstrated that an rAAV vector carrying the hTERTC27 gene (rAAV-hTERTC27) is effective in suppressing tumor growth and tumorigenicity in a subcutaneous human U87-MG glioblastoma xenograft model in nude mice. However, about 5-6 weeks after rAAV-hTERTC27 treatment, the residual tumors recurred and subsequently resulted in the death of the animals. 13 There are several drawbacks of rAAV for in vivo gene transfer, including the relatively low expression level and the slow onset of transgene expression. In fact, one of the rate-limiting steps of rAAV-mediated gene expression is the conversion of its single-strand DNA genome into double-strand template for transcription. 14, 15 This property puts a limit on the antitumor effect of therapeutic gene in that sufficient gene expression needs to come into effect before the animals succumb to excessive tumor burden. Therefore, development of gene delivery system with higher transduction efficiency is urgently needed. Previous studies have demonstrated that adenovirus E4 open reading frame 6 (E4 ORF6) facilitates the second-strand synthesis.
14 The direct role of E4 ORF6 in increasing rAAV vector transduction could be exploited by dual vector systems involving both adenovirus (rAdv) and rAAV. Such a combination could combine efficient gene transduction (rAdv and rAAV) with long-term persistence (rAAV).
We have shown earlier that a nonimmunogenic level of rAdv-BMP2 can greatly enhance rAAV-BMP2-mediated osteoinductive activity and result in new bone formation in vivo in immunocompetent rats. 16 This finding suggests that using an rAAV and rAdv cocktail in cancer gene therapy could be a desirable way of enhancing the gene expression level. In this study, we investigated the therapeutic efficacy of the cocktail vector system carrying the hTERTC27 gene in human GBM. Our results show that rAdv can greatly enhance the transduction efficiency of rAAV in vivo and that the rAAV-hTERTC27/rAdv-hTERTC27 cocktail vectors produce a synergistic therapeutic effect as compared to rAAV-hTERTC27 or rAdv-hTERTC27 alone. These novel findings suggest that the combination of rAAV-hTERTC27 and rAdv-hTERTC27 is potentially a promising treatment for GBM and that the rAAV/rAdv cocktail vector system warrants further development for cancer gene therapy.
Materials and methods

Cell culture
Human glioblastoma U87-MG cells (ATCC, Rockville, MD) were cultured in minimum essential medium supplemented with 10% fetal bovine serum (Invitrogen, Carlsbad, CA) and were maintained at 37 1C in 5% CO 2 incubator.
Preparation of recombinant adeno-associated virus and adenovirus The cDNAs encoding the 27 kD C-terminal fragment of hTERT (hTERTC27), luciferase and enhanced green fluorescent protein (EGFP) were obtained by PCR using the pCI-neo-hTERT, 11 pGEM-luc (Promega, Madison, WI) and pEGFP-N1 (BD Biosciences, San Jose, CA) as templates, respectively. The hTERTC27, luciferase and EGFP cDNAs were subcloned into the EcoRI and XhoI sites of pAM/CAG-WPRE-BGH-polyA plasmid 17, 18 to generate the rAAV packaging plasmids, pAAV-CAGhTERTC27, pAAV-CAG-luc and pAAV-CAG-EGFP, respectively. Recombinant AAV carrying hTERTC27 (rAAV-hTERTC27), luciferase (rAAV-luc) or EGFP (rAAV-EGFP) was produced by transient expression method using human embryonic kidney 293 cells, in accordance with a previously described procedure. 17, 18 The viruses were purified using HiTrap Heparin column chromatography (Sigma Chemical Co., St Louis, MO), and the viral genome titer was determined by TaqMan real-time PCR (Perkin-Elmer Biosystems, Foster City, CA). The viral stock was concentrated by Amicon (Millipore, Billerica, MA) and was kept at À80 1C prior to use.
For construction of recombinant adenovirus vectors, cDNA encoding hTERTC27 or luciferase was first cloned into an adenovirus expression vector pAd/CMV/DEST (Invitrogen) to generate pAd-hTERTC27 and pAd-luc plasmids, respectively. The control plasmid without any insert, pAd-null, was also constructed. The recombinant adenoviruses, rAdv-hTERTC27, rAdv-luc and rAdv-null, were produced by transfecting 293A cells with pAdhTERTC27, pAd-luc and pAd-null, respectively, using Lipofectamine 2000 reagent (Invitrogen). The viruses were then desalted, concentrated through cesium chloride gradients and purified. The purified viruses were stored at À80 1C in viral stock solution (10 mM Tris pH 8.0, 2 mM MgCl 2 , 4% sucrose). Viral titer was finally determined using tissue culture infectious dose 50 method (AdEasy Vector System Application Manual; Qbiogene, Carlsbad, CA). 9 PFU of rAdv was injected directly into the tumors at three different locations using a 10-ml microsyringe (Hamilton, Reno, NV). Tumor size was measured every week by a caliper, and tumor volume (V) was calculated as volume ¼ 0.5 Â length Â width 2 . In compliance with the UKCCCR Guidelines for the Welfare of Animals in Experimental Neoplasia, mice were euthanized when tumor burdens were greater than 10% of their body weight or when tumor became excessively necrotic.
Reverse transcription-polymerase chain reaction U87 tumor tissues were disrupted by a Polytron homogenizer (Brinkmann, Westbury, NY), and total RNA was extracted using Trizol reagent (Invitrogen). First-strand cDNA was synthesized from 5 mg total RNA by the SuperScript III First-Strand cDNA Synthesis System (Invitrogen), in accordance with the manufacturer's instructions. The sequences of the PCR primers for foreign hTERTC27 are hTERTC27-F (5 0 -TGTCTCAT CATTTTGGCAAAGAATTG-3 0 ) and hTERTC27-R (5 0 -TCAGTCCAGGATGGTCTTG-3 0 ); for glyceraldehyde-3-phosphate dehydrogenase are GAPDH-F (5 0 -TGCCTCCTGCACCACCAACT-3 0 ) and GAPDH-R (5 0 -CCCGTTCAGCTCAGGGATGA-3 0 ). Each 50 ml reaction contained 50 pmol of primers, 20 mM dNTPs and 2.5 U Taq Polymerase (Invitrogen). PCRs were carried out with an initial denaturation step of 5 min at 94 1C, followed by 30 cycles of 1 min at 94 1C, 1 min at 55 1C and 1 min at 72 1C, and an extension step of 10 min at 72 1C. The PCR products were electrophoresed on 1% ethidium bromide-stained agarose gel and visualized under a UV transilluminator.
Histological staining U87 tumor tissues were freshly isolated from the nude mice and fixed with 10% buffered formalin. The fixed tissues were dehydrated in a graded series of ethanol and embedded in paraffin. The tissue block was then sectioned in 5 mm thickness with a microtome. For histological analysis, sections were deparafinized with xylene, rehydrated in a graded ethanol series and stained with hematoxylin and eosin. TdT-mediated dUTP nick end labeling assay was performed using the in situ cell death detection kit (POD) (Roche, Indianapolis, IN).
Optical in vivo imaging U87-MG cells in exponential growth phase were harvested and resuspended in PBS at a density of 1 Â 10 7 cells per ml. The cells (1 Â 10 6 cells) were then inoculated subcutaneously at the right dorsal flank of each nude mouse. When tumors grew to a size of 3 mm in diameter, the mice were divided into different groups. rAAV-luc, rAdv-luc, rAdv-luc/rAAV-null, rAAV-luc/rAdv-null or rAAV-luc/rAdv-luc in a volume of 30 ml was injected directly into the tumors using a 50-ml microsyringe (Hamilton). Luciferase expression in the injected nude mice was monitored at different time points using a CCDbased optical in vivo imaging system (IVIS Imaging System 100 Series; Caliper Life Sciences, Hopkinton, MA). Mice were anesthetized, and D-luciferin (Xenogen) at a dose of 150 mg per gram mouse body weight was injected intraperitoneally 10 min before the images were taken. The intensity of light production was evaluated and represented in a color scale (photons per s per cm 2 ), with red being regions with the highest intensity and blue being regions with the lowest intensity.
Statistical analysis
Statistical analysis was performed using a one-way analysis of variance (and nonparametric) followed by Bonferroni test. Differences were considered significant when a P-value is o0.05.
Results
A nontherapeutic dose or therapeutic dose of rAdv vectors significantly enhanced the efficacy of rAAVhTERTC27 in inhibiting the growth of glioblastoma xenografts in nude mice We first investigated whether rAdv-null could enhance the transduction efficiency of rAAV-EGFP U87-MG cells in vitro. This cell line was chosen in this study because it is one of the most tumorigenic GBM cell lines identified to date. The cells were infected with either rAAV-EGFP (MOI ¼ 10 Figure 1A) . In contrast, the addition of rAdv-null increased the transduction efficiency to nearly 90% (Supplementary Figure 1B) .
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To evaluate the in vivo antitumor effect of rAAVhTERTC27 plus rAdv, nude mice with U87 glioblastoma xenografts were given an intratumoral injection of different combinations of rAAV-hTERTC27 and rAdv vectors as indicated in Table 1 and Figure 1a . As compared to the control PBS-, rAdv-null-, rAdvhTERTC27 (1 Â 10 8 PFU)-, rAAV-EGFP-or rAAV-EGFP/rAdv-null-injected mice, rAAV-hTERTC27 or rAdv-hTERTC27 at therapeutic dose (2.5 Â 10 9 PFU) treatment significantly prolonged the median survival from about 5 weeks to 7-8 weeks. When rAAVhTERTC27 was combined with a low dose (1 Â 10 8 PFU) of rAdv-null or rAdv-hTERTC27, the median survival was further extended to about 10 weeks. These results indicate that a low nontherapeutic dose of rAdv vector carrying either a therapeutic or nontherapeutic gene can enhance the antitumor effect of rAAVhTERTC27. Importantly, 25% of the mice in these treatment groups had complete tumor regression and remained tumor-free up to 30 weeks post-treatment (Figure 1a) .
In agreement with the survival data, a low dose (1 Â 10 8 PFU) of rAdv-null and rAdv-hTERTC27 was equipotent in enhancing the efficacy of rAAV-hTERTC27 in reducing the tumor growth (Figure 1b) . Six weeks after treatment, tumors in the cocktail therapy groups (rAAV-hTERTC27/rAdv-null and rAAV-hTERTC27/ rAdv-hTERTC27) were markedly smaller than those treated with rAAV-hTERTC27 or rAdv-hTERTC27 (2.5 Â 10 9 PFU) alone. The mean tumor volumes of rAAV-hTERTC27, rAdv-hTERTC27 (2.5 Â 10 9 PFU), rAAV-hTERTC27/rAdv-null and rAAV-hTERTC27/ rAdv-hTERTC27 treatment groups on the sixth week after intratumoral treatment were 1569.9 ± 124.6, 1719.9±124.6, 781.9±122 and 767.7±134.3 mm 3 , respectively (Figure 1b) .
We also examined the efficacy of the cocktail therapy by combining a therapeutic dose (2.5 Â 10 9 PFU) of rAdvhTERTC27 with rAAV-hTERTC27. The median survival rate of the treated mice further increased to 12.8 ± 1.9 weeks, and a 38% complete tumor regression rate was observed (Table 1 and Figure 1a) . The mean tumor volume of the mice injected with a therapeutic dose of rAAV-hTERTC27/rAdv-hTERTC27 was the smallest in all the treatment groups throughout the experimental period (Figures 1b and c) .
rAAV-hTERTC27/rAdv cocktail treatment led to necrosis in the U87-MG xenografts Five to six weeks after the intratumoral treatment, nearly all the mice in the control groups including PBS-, rAAV-EGFP-, rAdv-hTERTC27 (1 Â 10 8 PFU)-and rAdv-nulltreated groups were killed because their tumor burdens exceeded 10% of their body weight. In contrast, the mean tumor volumes of all the mice treated with rAAVhTERTC27 alone, rAdv-hTERTC27 (2.5 Â 10 9 ) alone, rAAV-hTERTC27/rAdv-null or rAAV-hTERTC27/ rAdv-hTERTC27 were about 60-80% less than those of the control mice. To examine how hTERTC27 inhibits the growth of U87-MG cells in vivo, we collected the tumor samples from each group of mice at day 21 post-treatment Abbreviations: EGFP, enhanced green fluorescent protein; PFU, plaque-forming unit; rAAV, recombinant adeno-associated virus; rAdv, adenovirus; v.g., viral genome; PBS, phosphatebuffered saline. *Po0.05 as compared to PBS-, rAdv-null-, rAAV-EGFP-, rAdv-hTERTC27 (1 Â 10 8 PFU)-and rAAV-EGFP/rAdv-null-injected mice; n ¼ 8. Figure 1 Effect of rAAV-hTERTC27 and rAAV-hTERTC27/rAdv cocktail treatment on the growth of glioblastoma xenografts. (a) The rAAVhTERTC27-based treatments significantly prolonged the survival of nude mice inoculated with U87-MG cells. Complete tumor regression was observed in 25-38% of the nude mice in the rAAV-hTERTC27/rAdv cocktail treatment groups. rAAV-hTERTC27 combined with a therapeutic dosage of rAdv-hTERTC27 was the most effective treatment in prolonging the survival of the U87 tumor-bearing nude mice. (b) A time-course study on tumor growth was done on the tumor-bearing nude mice with various treatments as indicated. All rAAV-hTERTC27-based treatments markedly inhibited tumor growth. A combination of rAAV-hTERTC27 and a low level of rAdv-null or rAdv-hTERTC27 was more effective than rAAV-hTERTC27 alone. The treatment of rAAV-hTERTC27 plus a therapeutic dosage of rAdv-hTERTC27 exerted a more powerful antitumor effect. The arrow indicates the time when tumor cell inoculation and intratumoral injection were performed. **Po0.01, rAAV-hTERTC27 or rAdvhTERTC27 (2.5 Â 10 9 PFU) versus the control PBS-, rAdv-null-, rAdv-hTERTC27 (1 Â 10 8 PFU)-, rAAV-EGFP-and rAAV-EGFP/rAdv-nulltreated groups; *Po0.05, rAAV-hTERTC27/rAdv-hTERTC27 or rAAV-hTERTC27/rAdv-null versus rAAV-hTERTC27 or rAdv-hTERTC27 (2.5 Â 10 9 PFU). (c) Photographs of the tumor-bearing nude mice on day 21 after various treatments as indicated. EGFP, enhanced green fluorescent protein; PFU, plaque-forming unit; rAAV, recombinant adeno-associated virus; rAdv, adenovirus.
Treatment of glioblastoma by combination of rAAV-hTERTC27 and Adv Y Gao et al and then performed reverse transcription-polymerase chain reaction (RT-PCR) and histological analysis. The expression of hTERTC27 transcript in the tumor samples was confirmed by RT-PCR ( Figure 2a) . As revealed by hematoxylin and eosin staining, areas of necrosis were consistently observed in all the samples treated with rAAV-hTERTC27 alone, rAdv-hTERTC27 (2.5 Â 10 9 PFU) alone or rAAV-hTERTC27/rAdv (Figures  2d-g ), but not in those treated with rAAV-EGFP or rAdv-null (Figures 2b and c) . TdT-mediated dUTP nick end labeling staining also showed that contrary to the control tissues (Figures 3a and b) , prominent apoptosis was found in all the mice treated with rAAV-hTERTC27, rAdv-hTERTC27 (2.5 Â 10 9 PFU) or rAAV-hTERTC27/ rAdv cocktail vectors, especially in the rAAV-hTERTC27/ rAdv-hTERTC27-treated mice (Figures 3c-f ).
The addition of rAdv to rAAV differentially altered the pattern and magnitude of transgene expression Our in vitro data showed that a low level of rAdv-null can significantly enhance the transduction efficiency of rAAV-EGFP at 48 h post-transfection. Therefore, we 
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Y Gao et al investigated the in vivo gene expression profiles of the rAAV/rAdv cocktail vector system using luciferase as a reporter gene. rAAV-luc (1.5 Â 10 11 v.g.) displayed a typical latent sustained expression (LSE) pattern, in which luciferase expression could only be detected 7 days after intratumoral injection (Figures 4a and f) . In contrast, rAdv-luc (2.5 Â 10 9 PFU) exhibited an early transient expression (ETE) pattern. The luciferase expression peaked at 24-48 h and then quickly decreased to the basal level 7 days after treatment (Figures 4b and f) .
Addition of a therapeutic dose of rAAV-null to rAdv-luc could augment the ETE peak by approximately 80%, suggesting that rAAV may enhance rAdv-mediated expression (Figures 4c and g ). Addition of a low dose (1 Â 10 8 PFU) or a therapeutic dose of rAdv-null (2.5 Â 10 9 PFU) to rAAV-luc (1.5 Â 10 11 v.g.) abrogated the LSE of rAAV-luc by 30% and displayed a marked increase in the ETE peak of rAdv-luc by fourfold, starting as early as 1 day after intratumoral injection (Figures 4d  and h) . Strikingly, the combination of rAAV-luc (1.5 Â 10 11 v.g.) and a therapeutic dose (2.5 Â 10 9 PFU) of rAdv-luc showed a synergistic increase of more than 15-fold in the ETE peak and twofold in the LSE as compared to the rAdv-luc and rAAV-luc alone, respectively (Figures 4e and i) .
Discussion
Several in vitro studies have reported that the transduction efficiency of rAAV-based vectors can be significantly augmented by simultaneous treatment with genotoxic chemicals such as hydroxyurea or with some physical agents such as ultraviolet. 19, 20 Ferrari et al. 14 demonstrated a 100-to 1000-fold increase in transduction Figure 3 Analysis of apoptosis in the U87-MG tumor tissues by TUNEL staining. U87-MG tumors were collected, fixed and sectioned for TUNEL staining 21 days after intratumoral injection of (a) rAAV-EGFP (1.5 Â 10 11 v.g.); (b) rAdv-null (1 Â 10 8 PFU); (c) rAdv-hTERTC27 (2.5 Â 10 9 PFU); (d) rAAV-hTERTC27 (1.5 Â 10 11 v.g.); (e) rAAV-hTERTC27 (1.5 Â 10 11 v.g.) plus rAdv-null (1 Â 10 8 PFU); (f) rAAV-hTERTC27 plus rAdv-hTERTC27 (2.5 Â 10 9 PFU). EGFP, enhanced green fluorescent protein; PFU, plaque-forming unit; rAAV, recombinant adenoassociated virus; rAdv, adenovirus; v.g., viral genome; TUNEL, TdT-mediated dUTP nick end labeling.
Treatment of glioblastoma by combination of rAAV-hTERTC27 and Adv Y Gao et al Treatment of glioblastoma by combination of rAAV-hTERTC27 and Adv Y Gao et al efficiency when 293 cells were coinfected with rAAV and adenovirus. Fisher et al. 15 have also reported that adenovirus could dramatically enhance AAV transduction in vitro. However, whether these in vitro data hold equally well in animal models is unclear.
It has been suggested that adenovirus gene products can promote the formation of episomal double-stranded rAAV DNA intermediates that are transcriptionally active. 15 This finding supported the hypothesis that rAdv-mediated increase in rAAV transduction is due to an enhanced rAAV second-strand synthesis. It is reasonable to suggest that adenovirus helper activities can increase rAAV transduction by altering rAAV-mediated transgene expression from stable to transient episomal expression. Our in vivo optical imaging data showed that combination of rAAV-luc plus rAdv-luc at therapeutic dose could increase both the ETE and LSE of luciferase. To our knowledge, this is the first report describing the existence of two expression peaks in rAAV/rAdvmediated transduction in vivo.
The ETE peak was about 15-fold of that induced by rAdv-luc alone and fourfold of that induced by rAAVluc/rAdv-null cocktail vectors. The significant increase in the magnitude of the ETE peak may represent a synergistic effect induced by the enhancement of transduction efficiency of rAAV-luc by rAdv and that of rAdvluc by rAAV. A previous transfection study using adenovirus genomic DNA indicated that the enhancement of in vitro rAAV transduction by rAdv was neither facilitated by adenovirus-mediated viral uptake nor dependent on the AAV gene cassette, but was instead dependent on rAdv gene expression. For example, it has been reported that the E4 ORF6 is involved in an immediate early step of the AAV life cycle, namely the conversion of single strand to double strand genomic DNA.
14 The second strand synthesis could be substantially improved by the expression of adenovirus genes E1 and E4, in which E4 ORF6 was sufficient and necessary to mediate this enhancement effect. 14, 15 Therefore, E4 ORF6 provided by adenovirus might have a significant effect on the use of rAAV vectors in gene therapy. In the present study, as the E1 and E3 regions in rAdv had been deleted, we hypothesized that E4 ORF6 in adenovirus genome might play a pivotal role in the dramatic increase of rAAV-mediated transduction. Nevertheless, the mechanism by which rAAV enhances rAdv-mediated transgene expression is at present unclear.
The LSE phase induced by rAAV-luc/rAdv-luc was, respectively, 2-and 10-fold of that induced by rAAV-luc and rAdv-luc at day 20 after intratumoral injection. It took about 10 days for the luciferase expression to reach a steady level. The observation that a transient and high level of luciferase expression preceded a steady luciferase expression level was probably due to the loss of the helper function of rAdv at later time points beyond day 10. Although the precise mechanism by which adenovirus interacts with rAAV to enhance its transduction in vivo has not been well understood; our experimental data indicated that rAAV/ rAdv cocktail vector is a promising gene delivery system to transfer therapeutic genes for cancer gene therapy.
In our animal studies, complete tumor regression was observed in 25% of tumor-bearing mice treated with rAAV-hTERTC27 plus a low dose of rAdv and in 38% of mice treated with rAAV-hTERTC27 plus a therapeutic dose of rAdv-hTERTC27. On the basis of the histological analyses of the tumor samples, a large number of apoptotic and necrotic cells was found in the tumor tissues isolated from rAAV-hTERTC27-, rAAVhTERTC27/rAdv-null-and rAAV-hTERTC27/rAdvhTERTC27-treated mice, indicating that the antitumor effect of hTERTC27 was mediated, at least in part, by increased apoptosis and necrosis.
One major obstacle to viral vector-based gene therapy is the generation of host immune responses directed against the vectors or the transgene products. In general, cytotoxic T cells are responsible for eradicating the transduced cells, whereas antibody-producing plasma cells secrete specific antibodies that neutralize the viral vectors or the transgene products. 21, 22 It has been demonstrated that rAdv at high titers can trigger significant host inflammatory responses, leading to rapid loss of vector and transgene. 23, 24 In contrast, rAAV has relatively low immunogenicity, and the transgene expression can be maintained for prolonged periods of time. 25, 26 In our nude mouse xenograft model, the rAAV/rAdv cocktail vectors or hTERTC27 protein expressed in the tumor cells can also induce both cellular and humoral immune responses. Nevertheless, the immune responses elicited by the cocktail viral vectors or hTERTC27 protein are likely to be greatly attenuated because nude mice are immunodeficient. 27 In fact, our nude mouse model actually mimics the immunosuppressive conditions commonly found in GBM patients. 28, 29 It is also worth noting that GBM is located in an immune-privileged site primarily due to the presence of the blood-brain barrier and the lack of draining lymphatics in the central nervous system. 30 Under normal conditions, only activated T cells can cross the blood-brain barrier. 31 Because the immune cells have limited access to the central nervous system, we expect that in the clinical scenario in which the rAAVhTERTC27/rAdv-hTERTC27 cocktail vectors are injected intracranially, the expression level of hTERTC27 in the brain will be similar to that observed in the mice. Further preclinical studies in an intracranial GBM model are instrumental in validating the in vivo therapeutic efficacy of the rAAV-hTERTC27/rAdv-hTERTC27 cocktail vectors.
In conclusion, using optical in vivo imaging technology, we have demonstrated for the first time that adenovirus can enhance the in vivo transduction efficiency of rAAV and vice versa. The observation that rAAV transduction can be dramatically enhanced by coinfection with rAdv offers the prospect of overcoming the apparent biological limitation of rAAV and optimizing the potential of this gene delivery system. These novel findings also suggest that the combination of rAAV-hTERTC27 and rAdvhTERTC27 vector at therapeutic dose is potentially a promising treatment for GBM and that this rAAV/rAdv cocktail vector system warrants further development for cancer gene therapy.
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